Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 16, 2026, 3:50 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–45 of 21 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: RPC-1063 Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Drug Interaction Study of the Effect on Cyclosporine on Ozanimod and Major Active Metabolites

NCT04149678
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Ozanimod, Cyclosporine
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Aug 23, 2020 · Synced Sep 16, 2026, 3:50 PM EDT
Recruiting Phase 4 Interventional

Prospective Evaluation of Sequencing From antiCD-20 Therapies to Ozanimod

NCT06529406
View directory record Official record
Conditions
Relapsing Multiple Sclerosis
Interventions
Ozanimod
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
3
States / cities
Aurora, Colorado • Las Vegas, Nevada • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 17, 2025 · Synced Sep 16, 2026, 3:50 PM EDT
Completed Phase 3 Interventional Results available

Induction Study #2 of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn's Disease

NCT03440385
View directory record Official record
Conditions
Crohn Disease
Interventions
Ozanimod, Placebo
Drug · Other
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 75 Years
Enrollment
606 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
81
States / cities
Scottsdale, Arizona • La Jolla, California • Lancaster, California + 67 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2024 · Synced Sep 16, 2026, 3:50 PM EDT
Recruiting No phase listed Observational

Understanding Ozanimod's MOA Via Mass Cytometry in Ulcerative Colitis

NCT06311123
View directory record Official record
Conditions
Ulcerative Colitis, Ulcerative Colitis Chronic Moderate
Interventions
Not listed
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Mar 14, 2024 · Synced Sep 16, 2026, 3:50 PM EDT
Withdrawn No phase listed Observational

Define Predictors of Response to Ozanimod in UC Discovering Biomarkers in the Management of Ulcerative Colitis

NCT05809583
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Ozanimod
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 3, 2025 · Synced Sep 16, 2026, 3:50 PM EDT
Active, not recruiting No phase listed Observational

A Study to Evaluate the Safety of Ozanimod Exposure During Pregnancy in Women With Ulcerative Colitis and Their Infants

NCT06126835
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Ozanimod, Conventional therapy, Advanced therapy
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 49 Years · Female only
Enrollment
2,828 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2032
U.S. locations
1
States / cities
Eden Prairie, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 30, 2024 · Synced Sep 16, 2026, 3:50 PM EDT
Active, not recruiting No phase listed Observational

A Study to Evaluate the Safety of Ozanimod Exposure During Pregnancy in Women With Multiple Sclerosis and Their Infants

NCT06133049
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Ozanimod, Select DMTs other than ozanimod, No DMTs
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 49 Years · Female only
Enrollment
2,961 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2031
U.S. locations
1
States / cities
Eden Prairie, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 14, 2023 · Synced Sep 16, 2026, 3:50 PM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety Trial of RPC1063 for Moderate to Severe Crohn's Disease

NCT02531113
View directory record Official record
Conditions
Crohn's Disease
Interventions
RPC1063
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 75 Years
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
13
States / cities
Tucson, Arizona • Largo, Florida • Palmetto Bay, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Jan 21, 2021 · Synced Sep 16, 2026, 3:50 PM EDT
Recruiting No phase listed Observational

A Study of Ozanimod in Pregnant Women With Ulcerative Colitis and Their Offspring

NCT05953402
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Not listed
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
Female only
Enrollment
1,182 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2034
U.S. locations
1
States / cities
Wilmington, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 14, 2026 · Synced Sep 16, 2026, 3:50 PM EDT
Terminated Phase 3 Interventional Results available

Induction Study #1 of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn's Disease

NCT03440372
View directory record Official record
Conditions
Crohn Disease
Interventions
Ozanimod, Placebo
Drug · Other
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 75 Years
Enrollment
625 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
107
States / cities
Peoria, Arizona • North Little Rock, Arkansas • Camarillo, California + 84 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2025 · Synced Sep 16, 2026, 3:50 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of Ozanimod in Relapsing Multiple Sclerosis

NCT02047734
View directory record Official record
Conditions
Relapsing Multiple Sclerosis
Interventions
Ozanimod, Ozanimod placebo, Interferon beta-1a, Interferon beta-1a placebo
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 55 Years
Enrollment
1,320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
35
States / cities
Phoenix, Arizona • Tucson, Arizona • Berkeley, California + 17 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2021 · Synced Sep 16, 2026, 3:50 PM EDT
Completed No phase listed Observational

Risk Perception in Multiple Sclerosis

NCT05528666
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
High Efficacy Therapy (HET), Non High Efficacy Therapy (Non-HET)
Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
4,361 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 7, 2022 · Synced Sep 16, 2026, 3:50 PM EDT
Active, not recruiting Phase 4 Interventional

Determining the Effectiveness of earLy Intensive Versus Escalation Approaches for RRMS

NCT03535298
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
Early Highly Effective Therapies Group, Escalation Therapies Group
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 60 Years
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
15
States / cities
Aurora, Colorado • Minneapolis, Minnesota • Rochester, Minnesota + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 30, 2026 · Synced Sep 16, 2026, 3:50 PM EDT
Completed Phase 3 Interventional Results available

Safety Study to Evaluate Immune Response of Vaccines in Participants With Relapsing Forms of Multiple Sclerosis Who Receive Ozanimod Compared to Non-Pegylated Interferon (IFN)-β or No Disease Modifying Therapy

NCT05028634
View directory record Official record
Conditions
Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting
Interventions
Tetanus, diphtheria, and acellular pertussis vaccine, Pneumococcal polysaccharide vaccine, Seasonal influenza vaccine
Biological
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 65 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
29
States / cities
Palo Alto, California • Colorado Springs, Colorado • Southington, Connecticut + 26 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2025 · Synced Sep 16, 2026, 3:50 PM EDT
Completed Phase 3 Interventional Results available

Study of Ozanimod (RPC1063) in Relapsing Multiple Sclerosis (MS)

NCT02294058
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Ozanimod, Interferon beta-1a, Placebo to ozanimod, Placebo to interferon beta-1a
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 55 Years
Enrollment
1,346 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
40
States / cities
Phoenix, Arizona • Tucson, Arizona • Berkeley, California + 35 more
Source: ClinicalTrials.gov public record
Updated Nov 24, 2020 · Synced Sep 16, 2026, 3:50 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Taste Assessment of Ozanimod

NCT05001152
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Ozanimod
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
25 Years to 80 Years
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
2
States / cities
Woburn, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 17, 2023 · Synced Sep 16, 2026, 3:50 PM EDT
Recruiting Phase 3 Interventional

Study to Evaluate the Effectiveness and Safety of Ozanimod Compared to Fingolimod in Children and Adolescents With Relapsing Remitting Multiple Sclerosis

NCT06408259
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
Ozanimod, Fingolimod, Placebo
Drug · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
10 Years to 17 Years
Enrollment
194 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2036
U.S. locations
12
States / cities
Loma Linda, California • Sacramento, California • Tampa, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Sep 16, 2026, 3:50 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Efficacy and Safety Study of Ozanimod (RPC1063) in Relapsing Multiple Sclerosis Patients

NCT01628393
View directory record Official record
Conditions
Relapsing Multiple Sclerosis
Interventions
Ozanimod, Placebo
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 55 Years
Enrollment
258 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
6
States / cities
Berkeley, California • Fresno, California • Sacramento, California + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2021 · Synced Sep 16, 2026, 3:50 PM EDT
Completed Phase 1 Interventional

Pharmacokinetics and Pharmacodynamics Study of RPC1063 in RMS

NCT02797015
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
RPC1063
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 55 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
6
States / cities
Long Beach, California • San Francisco, California • Raleigh, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2018 · Synced Sep 16, 2026, 3:50 PM EDT
Active, not recruiting Not applicable Interventional

Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Trial

NCT03500328
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
Natalizumab/natalizumab-sztn, Alemtuzumab, Ocrelizumab, Rituximab/rituximab-arrx/rituximab-abbs/rituximab-pvvr, Cladribine, Ofatumumab, Ublituximab-xiiy, Ocrelizumab and hyaluronidase-ocsq, Glatiramer acetate, Interferons (intramuscular, subcutaneous, pegylated) Teriflunomide, Fumarates (dimethyl, diroximel, monomethyl) Fingolimod, Siponimod, Ozanimod, Ponesimod
Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 60 Years
Enrollment
900 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
47
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 38 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Sep 16, 2026, 3:50 PM EDT
Terminated Phase 3 Interventional

Study Describing Cognitive Processing Speed Changes in Relapsing Multiple Sclerosis Subjects Treated With Ozanimod (RPC-1063)

NCT04140305
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
RPC-1063
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 65 Years
Enrollment
188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
56
States / cities
Birmingham, Alabama • Cullman, Alabama • Mobile, Alabama + 49 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2025 · Synced Sep 16, 2026, 3:50 PM EDT